MET detection in all tumor cells from more than 50% of the cases agreed with previous reports that showed MET protein overexpression in approximately 45% of ESCC samples (33,34), indicating that MET is a potential therapeutic target for ESCC patients. The gene discussed is MET; the disease is neoplasm.